Game changer in fighting cancer: BioCopy expands corporate portfolio with acquisition of start-up Perspix Biotech

"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"

11-Apr-2024 - BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...

Bayer and Aignostics to collaborate on next generation precision oncology

"Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare"

18-Mar-2024 - Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, ...

NovAliX and Max Planck join forces to advance Cryo-EM driven drug discovery

Collaboration will make vital process of translating scientific research and academic insights into real therapies more efficient and more effective

07-Mar-2024 - NovAliX, a specialized Contract Research Organization dedicated to enabling drug discovery, announces its long-term strategic partnership with the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen. Through this collaboration, NovAliX and the MPI aim to make the vital process ...

Cloud-based platform for analyzing cryo-EM data secures pre-seed investment

Dutch biotech start-up aims to accelerate the development of new active ingredients

04-Mar-2024 - CryoCloud, a biotech start-up based in Utrecht in the Netherlands, recently closed a financing round of 500,000 euros. The company has thus reached an important milestone on its way to optimizing cryo-electron microscopy (cryo-EM). CryoCloud was founded in 2021 by Munich-based Robert Englmeier, ...

Insamo launches with $12m funding to develop best-in-class membrane-permeable macrocyclic peptides

"Turn-key" solution from Insamo to revolutionise drug discovery

26-Feb-2024 - Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV). MRLV is a corporate venture arm of Merck & Co., Inc which invests in ...

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene

08-Jan-2024 - Galapagos NV announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates. Through this collaboration, ...

Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes

08-Nov-2023 - Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven ...

HeartBeat.bio raises € 4.5 million in Pre-Series A financing

New funds to drive development of organoid screening platform for cardiac drug discovery

03-Nov-2023 - HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, announced the closing of a € 4.5 million Pre-Series A round co-led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures. The financing ...

SRI spins off AI-powered drug discovery platform Synfini, Inc.

Synfini to commercialize and scale automated compound testing for rapid drug production

09-Oct-2023 - SRI International announced it is spinning off Synfini, a biosciences platform that accelerates the process by which pharmaceutical and other companies can design, synthesize, and bring to market molecules for drug development. The technology brings together a suite of software and hardware ...